Global Iparomlimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Iparomlimab market size was valued at US$ 64.82 million in 2025 and is forecast to a readjusted size of US$ 316 million by 2032 with a CAGR of 15.7% during review period.
Iparomlimab is a humanized monoclonal antibody designed to selectively target the programmed cell death protein 1 (PD‑1) pathway, functioning as an immune checkpoint inhibitor to restore and enhance anti‑tumor immune responses. By specifically binding to PD‑1 receptors expressed on T lymphocytes, it blocks inhibitory signaling interactions with PD‑L1 and PD‑L2, thereby relieving immune suppression, promoting T‑cell activation, proliferation, and cytotoxic activity against malignant cells. Engineered with an optimized IgG4 backbone to minimize off‑target effector functions and improve stability, it demonstrates favorable pharmacokinetic and safety profiles for clinical application. As a targeted immunotherapeutic agent, Iparomlimab is under clinical development for multiple solid tumors and hematological malignancies, often investigated in combination with other immunomodulatory antibodies to achieve synergistic anti‑cancer efficacy.In 2025, global Iparomlimab production reached approximately 120,000 vials
Iparomlimab, a PD-1 immune checkpoint inhibitor independently developed by Qilu Pharmaceutical, is built upon the proprietary MabPair® technology platform and enters the highly competitive tumor immunotherapy market with differentiated molecular design and clinical safety advantages. Its core market value is embodied in the world’s first-in-class combination antibody therapy with tuvonralimab, which delivers synergistic anti-tumor efficacy by simultaneously blocking the PD-1 and CTLA-4 pathways, demonstrating significant clinical benefits and application potential in indications such as recurrent or metastatic cervical cancer. Amid intensifying competition in the PD-1/PD-L1 inhibitor market, iparomlimab differentiates itself from conventional single-agent PD-1 products through the unique mechanism of combination therapy, treatment convenience independent of PD-L1 testing, and improved accessibility driven by insurance coverage. Future market expansion will rely on the advancement of multi-tumor clinical pipelines, penetration into primary healthcare markets, and international layout to build differentiated competitiveness in precision immunotherapy and combination treatment regimens. Concurrently, it faces multiple challenges including intense competition from a surge of domestic similar products, market penetration by international pharmaceutical giants, and rapid evolution of treatment paradigms. Its commercial performance and market share will be highly dependent on the speed of indication expansion, strength of clinical evidence, and coverage of commercialization channels.
This report is a detailed and comprehensive analysis for global Iparomlimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Iparomlimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Iparomlimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Iparomlimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Iparomlimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Iparomlimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Iparomlimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Qilu Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Iparomlimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
50 mg / 2 mL per vial
100 mg / 4 mL per vial
Market segment by Combination Therapy
Iparomlimab + bevacizumab
Iparomlimab + tuvonralimab
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Cervical Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
Others
Major players covered
Qilu Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Iparomlimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Iparomlimab, with price, sales quantity, revenue, and global market share of Iparomlimab from 2021 to 2026.
Chapter 3, the Iparomlimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Iparomlimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Iparomlimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Iparomlimab.
Chapter 14 and 15, to describe Iparomlimab sales channel, distributors, customers, research findings and conclusion.